Background: Hepatitis C virus infection is one of the main causes of chronic liver disease worldwide. Circulating miR-122 is considered a very promising biomarker due to good stability, high tissue specificity as a biomarker for necroinflammatory activity in patients with chronic hepatitis C. Aim of the study: To assess Microrna-122 As A Potential Biomarker for Liver Injury Resulted from Chronic Hepatitis C Infection. Patients and Methods: The study was conducted on 30 subjects (15 patients with CHC infection as confirmed by PCR analysis and 15 volunteers served as healthy control). We performed the following tests: serum ALT and AST, serum albumin and, total bilirubin, PT, PTT and INR, and serum viral load of HBV, HCV, and HIV by quantitative PCR. Results: Serum levels of bilirubin, PT, AST, and ALT were significantly higher in CHC group compared to the control group (p <0.05). The performed miRNA-122 analysis revealed a nonsignificant difference in serum miRNA-122 relative expression between CHC patients and healthy control (mean ΔΔCT (±SD) = -2.85 (±4.34) and-2.25 (±2.93), respectively, P =0.79). The level of miRNA-122 was higher in the serum of CHC patients. In the CHC groups, ALT activity was above the reference range of ALT with higher miRNA-122 expression. The results showed a nonsignificant positive correlation between the miRNA-122-fold change and the ALT activity (r=0.01, p=0.98). The best cutoff of miRNA-122 in the diagnosis of CHC is >5.34 with an area under curve (AUC) of 0.64 (95% CI [0.46 to 0.81]), sensitivity=60%, and specificity=50%. Conclusion: Serum miRNA-122 expression level is increased in adult CHC patients compared to healthy controls. Further studies have to be conducted on larger scale to confirm the relation between miRNA-122 and ALT levels.